Gossamer Bio, Inc. (GOSS)
Pre-Market:
| Previous Close | 0.8261 |
| Open | 0.9200 |
| Bid | 0.9695 x 300 |
| Ask | 1.0200 x 1000 |
| Day's Range | 0.8800 - 1.0900 |
| 52 Week Range | 0.4530 - 1.8800 |
| Volume | |
| Avg. Volume | 2,095,004 |
| Market Cap | 228.481M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
- Simply Wall St.
Gossamer Bio Decline Means Insider Profits Down To US$17k
Insiders who bought Gossamer Bio, Inc. ( NASDAQ:GOSS ) stock lover the last 12 months are probably not as affected by...
- Insider Monkey
13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
